Updates are available Correction dated 2021-04-22

Article History

Received: 9 November 2020

Accepted: 12 February 2021

First Online: 12 March 2021

Change Date: 22 April 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00737-021-01133-4

Declarations

:

: Ethical approval was obtained from the institutional review board of Massachusetts General Brigham (IRB reference # 2008P001861).For all participants, informed consent was obtained prior to data collection. Consent was obtained using Massachusetts Brigham IRB approved materials.

: All authors agree to publish the manuscript in the <i>Archives of Women’s Mental Health</i>.

: LSC: National Pregnancy Registry for Atypical Antipsychotics: Alkermes Biopharmaceuticals; Aurobindo Pharma; Janssen Pharmaceutica; Otsuka Pharmaceuticals; Sunovion Pharmaceuticals, Inc.; Teva Pharmaceuticals; Sage Therapeutics, Inc. Other Research Support: Brain & Behavior Research Foundation; JayMac Pharmaceuticals; National Institute on Aging; National Institutes of Health; National Institute of Mental Health; SAGE Therapeutics; Takeda/Lundbeck Pharmaceuticals Advisory/Consulting: Alkermes Biopharmaceuticals (through MGH Clinical Trials Network Initiative); JDS Therapeutics LLC; Praxis Precision Medicines, Inc. (through MGH Clinical Trials Network Initiative) Honoraria: None Royalty/patent, other income: None.ACV: Research Support: National Pregnancy Registry for Atypical Antipsychotics: Alkermes Biopharmaceuticals; Aurobindo Pharma; Janssen Pharmaceutica; Otsuka Pharmaceuticals;Sunovion Pharmaceuticals, Inc.; Teva Pharmaceuticals; Sage Therapeutics, Inc. Other Research Support: None; Advisory/Consulting: Up-to-Date; Speaking/Honoraria: None;Royalty/patent, other income: None.MPF: National Pregnancy Registry for Atypical Antipsychotics: Alkermes Biopharmaceuticals; Aurobindo Pharma; Janssen Pharmaceutica; Otsuka Pharmaceuticals; Sunovion Pharmaceuticals, Inc.; Teva Pharmaceuticals; Sage Therapeutics, Inc. Other research support: JayMac Pharmaceuticals LLC, SAGE Therapeutics; As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Advisory/Consulting: Advisory Boards: Eliem, Sage; Independent Data Safety and Monitoring Committee: Janssen (Johnson& Johnson), Novartis; Steering Committee for Educational Activities: Medscape; educational activities: WebMD. Speaking/Honoraria: None; Royalty/patent, other income: None.SHD: Consulting fees (e.g. advisory boards): Roche and UCB, and her institution received funding from Takeda for unrelated project; epidemiologist for the North American Antiepileptic Drugs pregnancy registry and advisor for the Antipsychotics Pregnancy Registry, which are funded by multiple companies; The Pharmacoepidemiology Program at the Harvard T.H. Chan School of Public Health is partially supported by training grants from Pfizer, UCB, Bayer and Asisa.LGM, AZS, SAM, TRC, AVY, PSC, DC: Nothing to disclose.